Sensyne Health PLC Sensyne and OMNY Health Sign Teaming Agreement (1672P)
15 Octubre 2021 - 1:00AM
UK Regulatory
TIDMSENS
RNS Number : 1672P
Sensyne Health PLC
15 October 2021
Sensyne Health and OMNY Health Sign Teaming Agreement to Support
Breakthrough Research Through the Power of Real World Data and
AI
Sensyne and OMNY will collaborate to develop new proposals to
life sciences companies and healthcare providers to use real world
data and advanced analytical tools to improve patient outcomes and
accelerate the development of new medicines
The Teaming Agreement allows OMNY to engage Sensyne's data
analytics tools and consulting services and provides Sensyne with
the potential to access OMNY Health's 22 million de-identified
patient records
Dover, DE and Atlanta, GA. Oxford, U.K. October 15, 2021 :
Sensyne Health plc (LSE: SENS) ("Sensyne"), the ethical Clinical AI
company, and OMNY Health ("OMNY"), the largest US-based real world
data network, today announced a strategic teaming relationship.
The arrangement establishes a nimble framework under which
Sensyne can contract for access to OMNY Health's platform of more
than 22 million de-identified patient records across all
therapeutic areas in support of Sensyne's data analytics work for
life science companies. In addition, Sensyne and OMNY have agreed
to work together on commercial projects for life science clients to
advance and accelerate ethical medical research. By bringing
biopharma clients a joint offering with OMNY real-world data and
Sensyne machine learning expertise, both companies-and their health
system partners-will have more opportunities to support important
life sciences research.
The OMNY data network complements Sensyne's existing global
medical research dataset of 22.1 million patients, ethically
sourced through strategic partnerships with US health systems and
the UK's National Health Service (NHS) trusts. With a data network
that spans over 50,000 providers across 40 states, OMNY's data
platform also offers control, security, and data governance to
maximize the utility of information while maintaining compliance
with US regulations. Sensyne will now have a new avenue to access
an additional 22 million unique patient records, significantly
enhancing the scale of real world data on which Sensyne can apply
its advanced machine learning and bringing the combined total of
de-identified patient data available for its research to over 44m
patients.
Derek Baird, President, North America, Sensyne Health said:
"This relationship has been forged on a mutual belief in the
power of real-world data to support breakthrough insights and
discoveries. The team at OMNY, like us, appreciate the complexity
of working with longitudinal clinical records, and the trust that
health systems place in our companies to analyse de-identified
patient data in an ethical, secure, and responsible way. We share
common philosophies and missions, and complementary approaches in
responsibly using real-world data to accelerate life science
research for clients. This is an exciting alliance, and we are
thrilled to be working together."
Mitesh Rao, MD, CEO, OMNY Health said:
"OMNY Health embraces the opportunity to work with Sensyne
Health's world-class machine learning team and data science
professionals, and is thrilled for Sensyne to join the platform. We
aim to revolutionize the healthcare ecosystem through our
equality-driven data network while unlocking transformative real
world data partnerships across the life sciences industry. This
collaboration with Sensyne Health creates even greater
possibilities to apply emerging technologies to the unparalleled
data we've assembled, enabling both companies to ethically innovate
on behalf of our respective partners, and most importantly, to
create better outcomes for patients."
Sensyne is working with life science partners on different types
of research projects across multiple disease areas. The actionable
insights from OMNY's longitudinal patient data sets will help them
with synthetic control arms, patient stratification, patient
identification and selection, plus important late-phase clinical
trial design, commercialisation, and health economic pricing
decisions.
-ENDS-
For more information please contact:
Sensyne Health ( www.sensynehealth.com +44 (0) 330 058
) 1845
Lord (Paul) Drayson PhD FREng, Chief Executive
Officer
Dr Richard Pye, Chief Financial Officer
Peel Hunt LLP (Nominated Adviser and Joint + 44 (0) 20 7418
Broker) 8900
Dr Christopher Golden
James Steel
Victoria Erskine
+ 44 (0) 20 3100
Liberum (Joint Broker) 2000
Bidhi Bhoma
Euan Brown
+44 (0) 77 0286
Consilium Strategic Communications 8207
Mary-Jane Elliott
Jessica Hodgson
CSCS ensynehealth@consilium-comms.com
Notes to editors
About Sensyne Health: www.sensynehealth.com
Sensyne Health plc (LSE: SENS) is a clinical artificial
intelligence company operating a unique business model - a
for-profit plc making a positive social impact, sharing the
financial returns it makes with health systems. The company applies
clinical AI in the healthcare and life science industries. In
healthcare, Sensyne delivers remote patient monitoring and
real-time decision-making systems for healthcare organizations and
their patients. In life sciences, Sensyne analyses large complex
anonymized data sets to help life sciences companies accelerate the
development of new medicines.
About OMNY : www.omnyhealth.com
OMNY Health connects patients, providers, and life sciences
companies through data and insights to accelerate life-changing
innovation. Our secure platform enables life sciences organizations
to engage in collaborative data and research partnerships
efficiently, compliantly, and at scale. OMNY Health is dedicated to
reimagining a future of patient-centered and evidence-based care
driven by a connected data ecosystem that links all parts of the
healthcare experience.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCFFFVFILLSLIL
(END) Dow Jones Newswires
October 15, 2021 02:00 ET (06:00 GMT)
Sensyne Health (LSE:SENS)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Sensyne Health (LSE:SENS)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024